AstraZeneca PLC (AZN) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Total Cash From Operating Activities Chart for AstraZeneca PLC
AstraZeneca PLC (AZN) operating cash flow for FY2025 was GBP 14.6B, a 22.9% change from FY2024. AstraZeneca PLC's operating cash flow grew from GBP 806.3M in 1990 to GBP 14.6B in 2025 (1707.6% over 35 years). Operating cash flow compound annual growth rate: 5-year CAGR of 24.9%, 10-year CAGR of 15.9%, 20-year CAGR of 3.9%.
Total Cash From Operating Activities (British Pounds)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- £177.73B
- Implied Share Price
- £114.60
- Enterprise Value
- £197.95B
- Revenue (TTM)
- £61.37B
- EBITDA
- £19.90B
- Profit Margin
- 17.02%
- Trailing P/E
- 23.15
- Forward P/E
- 15.08
- Price/Book (MRQ)
- 4.77
- Price/Sales (TTM)
- 2.90
- EV/EBITDA
- 13.12
- EV/Revenue
- 4.35
- Dividend Yield
- 2.76%
- Book Value
- £24.04
- Free Cash Flow (FY2025)
- £8.67B
- Free Cash Flow Yield
- 4.88%
Snapshot as of 15th August 2026 — not point-in-time controlled, may lag the live market by a few days.